Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestineSiissalo, S., De Waard, H., De Jager, M. H., Hayeshi, R., Frijlink, H. W., Hinrichs, W. L. J., Dinter-Heidorn, H., Van Dam, A., Proost, J. H., Groothuis, G. M. M. & De Graaf, I. A. M., Aug-2013, In : Drug Metabolism and Disposition. 41, 8, p. 1557-1565 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacokinetics, Toxicology and Targeting
- Pharmaceutical Technology and Biopharmacy
- Biopharmaceuticals, Discovery, Design and Delivery (BDDD)
- Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE)
- Center for Liver, Digestive and Metabolic Diseases (CLDM)
- Nanobiotechnology and Advanced Therapeutic Materials (NANOBIOMAT)
The inclusion of nanoparticles dispersed in a hydrophilic matrix is one of the formulation strategies to improve the bioavailability of orally administered Biopharmaceutics Classification System (BCS) class II and IV drugs by increasing their dissolution rate in the intestine. To confirm that the increased dissolution rate results in increased bioavailability, in vitro and in vivo animal experiments are performed, however, translation to the human situation is hazardous. In this study, we used a range of in vitro and ex vivo methods, including methods applying human tissue, to predict the in vivo oral bioavailability of a model BCS class II CB-1 antagonist, formulated as a nanoparticle solid dispersion. The enhanced dissolution rate from the nanoparticle formulation resulted in an increased metabolite formation in both rat and human precision-cut intestinal slices, suggesting increased uptake and intracellular drug concentration in the enterocytes. In Ussing chamber experiments with human tissue, both the metabolite formation and apical efflux of the metabolite were increased for the nanoparticulate solid dispersion compared with a physical mixture, in line with the results in intestinal slices. The pharmacokinetics of the different formulations was studied in rats in vivo. The nanoparticle formulation indeed improved the absorption of the cannabinoid receptor 1 (CB-1) antagonist and the delivery into the brain compared with the physical mixture. In conclusion, the combined approach provides a valuable set of tools to investigate the effects of formulation on the absorption of poorly soluble compounds in human intestine and may provide relevant information on the oral bioavailability in humans early in the development process. Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics.
|Number of pages||9|
|Journal||Drug Metabolism and Disposition|
|Publication status||Published - Aug-2013|
- 1 methyl 2 pyrrolidinone, 3 (4 chlorophenyl) n methyl 4 phenyl n' [4 (trifluoromethyl)piperidin 1 ylsulfonyl] 4,5 dihydro 1h pyrazole 1 carboxamidine, cannabinoid 1 receptor antagonist, drug metabolite, mannitol, nanoparticle, unclassified drug, animal experiment, animal tissue, area under the curve, article, cell level, controlled study, dispersion, drug absorption, drug bioavailability, drug blood level, drug brain level, drug distribution, drug dosage form comparison, drug formulation, drug mixture, drug solubility, drug uptake, ex vivo study, female, human, human tissue, in vitro study, in vivo study, intestine cell, jejunum, male, nonhuman, prediction, priority journal, rat, tablet compression